Mohan, Rinesh Ram and Abd. Rahim, Nour El Huda and A. Talib, Norlelawati and Mohamed Bakrim, Norbaiyah and Abdull Jalil, Mohd Asyraf and Mat Rasid, Siti Norain (2025) Comparative study of Apolipoprotein A1 levels in obese schizophrenia and controls. In: 1st International Biomedical Conference (IBC2025), 3rd September 2025, Kuantan, Pahang , Malaysia.
|
PDF (Abstract)
- Published Version
Download (2MB) | Preview |
Abstract
INTRODUCTION: Obesity commonly co-occurs in patients with schizophrenia, contributing to their elevated susceptibility to cardiovascular disease. Apolipoprotein A1 (Apo A1), the principal protein component of high-density lipoprotein (HDL), is known for its protective roles against inflammation and atherosclerosis; however, the relationship of obesity among individuals with schizophrenia remains unclear. OBJECTIVE(S): This study aimed to compare the plasma Apo A1 levels between individuals with schizophrenia and control subjects across both obese and non-obese groups. MATERIALS & METHODS: A total of 120 subjects participated in this comparative cross-sectional study. They were categorised into four subgroups: obese schizophrenia, obese control, non-obese schizophrenia, and non-obese control (n = 30 per group). Plasma Apo A1 concentrations were quantified using a sandwich Enzyme-Linked Immunosorbent Assay (ELISA). The Mann-Whitney U test was applied to nonnormally distributed obese groups, and Welch’s t-test to nonobese groups with unequal variances. RESULTS: Plasma Apo A1 levels were significantly reduced in individuals with schizophrenia across both obesity categories. In the obese participants, the schizophrenia group demonstrated significantly lower median Apo A1 (270.20 [153.36] mg/ dL) compared to obese controls (308.65 [132.85] mg/ dL) (p = 0.016). A similar trend was observed in the nonobese group, mean Apo A1 was also lower in non-obese schizophrenia participants (333.55 ± 131.03 mg/dL) than in non-obese controls (459.23 ± 206.92 mg/dL) (p = 0.004). These findings establish that schizophrenia independently lowers Apo A1 levels, while co-morbid obesity significantly exacerbates this deficit, increasing cardiovascular risk in these patients. CONCLUSION: Our findings show that individuals with schizophrenia have consistently lower Apo A1 levels regardless of obesity, suggesting the need to explore Apo A1 not only as a potential biomarker but also as a potential therapeutic target to improve their cardiovascular health and overall well-being.
| Item Type: | Proceeding Paper (Other) |
|---|---|
| Additional Information: | 6300/123605 |
| Uncontrolled Keywords: | Obesity, Schizophrenia, Apolipoprotein A1, Biomarkers |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine > RA790 Mental Health. Mental Illness Prevention |
| Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button): | Kulliyyah of Medicine > Department of Basic Medical Kulliyyah of Medicine Kulliyyah of Medicine > Department of Pathology & Lab Medicine |
| Depositing User: | Dr Nour El Huda Abd Rahim |
| Date Deposited: | 14 Oct 2025 13:18 |
| Last Modified: | 14 Oct 2025 14:00 |
| URI: | http://irep.iium.edu.my/id/eprint/123605 |
Actions (login required)
 |
View Item |
Download Statistics
Download Statistics